EMFAT
BHVN

Emerald Mutual Fund Advisers Trust’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Emerald Mutual Fund Advisers Trust’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-154,634
Closed -$22.5M – 232
2022
Q2 		$22.5M Sell
154,634
-108,256
-41% -$13.8M 1.31% 22
2022
Q1 		$31.2M Buy
262,890
+2,308
+0.9% +$288K 1.38% 19
2021
Q4 		$35.9M Buy
260,582
+35,181
+16% +$4.47M 1.27% 23
2021
Q3 		$31.3M Buy
+225,401
New +$28.1M 1.08% 33
2021
Q1 		– Sell
-76,124
Closed -$6.53M – 264
2020
Q4 		$6.53M Sell
76,124
-109,740
-59% -$9.3M 0.23% 118
2020
Q3 		$12.1M Sell
185,864
-253,284
-58% -$16.6M 0.54% 73
2020
Q2 		$32.1M Sell
439,148
-73,251
-14% -$3.9M 1.52% 10
2020
Q1 		$17.4M Buy
512,399
+53,790
+12% +$2.46M 1.09% 28
2019
Q4 		$25M Buy
458,609
+154,005
+51% +$7.63M 1.02% 26
2019
Q3 		$12.7M Sell
304,604
-1,438
-0.5% -$60.8K 0.56% 59
2019
Q2 		$13.4M Sell
306,042
-191,679
-39% -$10.8M 0.53% 71
2019
Q1 		$25.6M Buy
497,721
+17,403
+4% +$752K 1.03% 27
2018
Q4 		$17.8M Buy
480,318
+11,425
+2% +$412K 0.83% 40
2018
Q3 		$17.6M Buy
468,893
+123,103
+36% +$4.53M 0.59% 62
2018
Q2 		$13.7M Buy
345,790
+19,183
+6% +$609K 0.5% 84
2018
Q1 		$8.41M Buy
326,607
+43,109
+15% +$1.29M 0.33% 114
2017
Q4 		$7.65M Buy
283,498
+83,312
+42% +$2.29M 0.3% 116
2017
Q3 		$7.48M Sell
200,186
-152,374
-43% -$4.62M 0.31% 115
2017
Q2 		$8.81M Buy
+352,560
New +$8.12M 0.38% 96

Other funds holding BHVN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SFM
Soros Fund Management New York $9.12B AUM 30.69% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Emerald Mutual Fund Advisers Trust's BHVN Position: Q3 2022 in Review

Emerald Mutual Fund Advisers Trust sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q3 2022, closing a stake of 154,634 shares — an estimated $22.5M sold.

Emerald Mutual Fund Advisers Trust first reported a position in BHVN in Q2 2017 and held it in 19 quarters. The position peaked at $35.9M in Q4 2021. 240 funds tracked by Wall St. Rank hold BHVN as of Q3 2022.

  • Emerald Mutual Fund Advisers Trust reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q3 2022 after selling out during the quarter.
  • Emerald Mutual Fund Advisers Trust sold 154,634 Biohaven Pharmaceutical Holding Company Ltd. shares in Q3 2022, an estimated $22.5M.
  • Emerald Mutual Fund Advisers Trust first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q2 2017 and held it in 19 quarters.
  • Emerald Mutual Fund Advisers Trust's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $35.9M in Q4 2021.
  • 240 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q3 2022.

Based on Emerald Mutual Fund Advisers Trust's 13F filing for Q3 2022, filed 25 Oct 2022.